louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00661232: Multicenter Myocardial Viability Trial
Official title: An International, Multicenter Trial Assessing Myocardial Viability With Contrast - Enhanced Magnetic Resonance Imaging
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: Myocardial Viability
Delayed Enhancement Magnetic Resonance Imaging
Functional Recovery
Lead sponsor: CHI St. Luke's Health, Texas
Sponsor class: OTHER
Collaborators: name: Medtronic - MITG
First posted: 2008-04-18
Enrollment: 235
Sex: ALL
Minimum age (years): 21
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients were recruited from 9 institutions on 3 different continent. All patients recruited for the study had a history of angiographically documented chronic coronary artery disease and resting wall motion abnormalities, and were scheduled for cardiac revascularization (coronary artery bypass surgery or percutaneous intervention).

Brief summary: The purpose of this study is to test the hypothesis of whether contrast enhanced Magnetic Resonance Imaging can be used to predict improvement of the wall motion in regions of the heart with abnormal movement following bypass surgery or percutaneous angioplasty in various institutions across three continents.


Eligibility criteria: Inclusion Criteria:

* Age: \> 21 years and \< 85 years
* Sinus rhythm
* Weight \< 120 kg
* LVEF \> 30%
* Wall motion abnormality on Echo. or LV-gram
* Scheduled for revascularization - Angioplasty/Stent or CABG - within 30 days

Exclusion Criteria:

* Resting heart rate \> 100 bpm
* Frequent atrial or ventricular ectopy
* Severe aortic stenosis or HOCM
* Unstable angina
* Myocardial infarction within 14 days
* Active congestive heart failure
* Pregnancy
* Known allergy to gadolinium
* Contraindication to MRI

Primary outcomes:
measure: To examine whether the extent of irreversible myocardial injury as assessed by Delayed Enhancement Magnetic Resonance Imaging can predict the extent of functional recovery after revascularization in patients with chronic coronary artery disease (CAD).
timeFrame: 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: St. Luke's Episcopal Hospital
state: Texas
city: Houston
country: United States
facility: St. Luke's Episcopal Location
state: Texas
city: Brussels
country: Belgium
facility: Cliniques Universitaires St. Luc
city: Aarhus N
country: Denmark
facility: Skejby University Hospital
city: Maroussi
country: Greece
facility: Hygeia Hospital
city: Bangkoknoi
country: Thailand
facility: Siriraj Hospital
state: Bangkok
city: Leeds
country: United Kingdom
facility: Cardiac MRI Unit
Study officials:
affiliation: CHI St. Luke's Health, Texas
name: Scott D Flamm, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03253432: IN-TANDEM Familial Hypercholesterolemia Pilot Study
Official title: INTegrating Active Case-finding With Next-generation Sequencing for Diagnosis Through Electronic Medical Records (IN-TANDEM): Familial Hypercholesterolemia Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Familial Hypercholesterolemia
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: The Familial Hypercholesterolemia Foundation
name: Lancaster General Hospital
First posted: 2017-08-17
Enrollment: 378
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Randomly selected patients from University of Pennsylvania and Lancaster General Hospital with at least 1 cardiovascular comorbidity seen at hospital within the past five years.

Brief summary: The purpose of this study is to validate the use of the FH Foundation FIND FH® Algorithm as a clinical decision support tool. FIND FH (Flag/Identify/Network/Engage) is a national initiative that utilizes machine learning and data mining techniques to identify individuals whose profiles are consistent with FH patients. The algorithm will be tested in adults with at least one cardiovascular comorbidity. Study subjects will be asked to provide either a saliva, buccal or venous blood sample for DNA and biomarker analysis


Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* At least one cardiovascular co-morbidity or receiving treatment for a cardiovascular comorbidity
* Algorithm score 0-1
* Most recent encounter with a provider within five years of query date

Exclusion Criteria:

* Any medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study, or confound study data

Primary outcomes:
measure: Likelihood of having FH-causing mutation
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lancaster
country: United States
facility: Lancaster General Hospital
state: Pennsylvania
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
References:
citation: Qureshi N, Da Silva MLR, Abdul-Hamid H, Weng SF, Kai J, Leonardi-Bee J. Strategies for screening for familial hypercholesterolaemia in primary care and other community settings. Cochrane Database Syst Rev. 2021 Oct 7;10(10):CD012985. doi: 10.1002/14651858.CD012985.pub2.
Clinical trial NCT00743132: Novel Prediction Score for Postoperative Acute Renal Failure (ARF) Following Liver Resection
Official title: Novel Prediction Score for Postoperative Acute Renal Failure (ARF) Following Liver Resection
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Renal Failure
Keywords: evaluation
incidence
liver surgery
resection
impact
postoperative
mortality
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2008-08-28
Enrollment: 569
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with benign and malign liver diseases of the Swiss HPB (Hepato-Pancreato-Biliary) Center undergoing liver resection from 2002 - 2007

Brief summary: ARF is a frequent event after hepatic resection and therefore clinically highly relevant.

There is limited evidence on the incidence of postoperative ARF and its clinical relevance in patients undergoing liver resection.

This study will evaluate the incidence of acute renal failure (ARF) after liver resection and its impact on postoperative mortality.

Detailed description: ARF is a frequent event after hepatic resection and therefore clinically highly relevant.

There is limited evidence on the incidence of postoperative ARF and its clinical relevance in patients undergoing liver resection.

This study will evaluate the incidence of acute renal failure (ARF) after liver resection and its impact on postoperative mortality.

Eligibility criteria: Inclusion Criteria:

* Patient age \>/= 18 years
* Benign and malign liver diseases

Exclusion Criteria:

* Trauma cases

Primary outcomes:
measure: Predictor score
measure: Incidence of ARF Length of hospital stay
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: Swiss HPB (Hepato-Pancreato-Biliary) Center of the University Hospital Zurich
Study officials:
References:
citation: Slankamenac K, Breitenstein S, Held U, Beck-Schimmer B, Puhan MA, Clavien PA. Development and validation of a prediction score for postoperative acute renal failure following liver resection. Ann Surg. 2009 Nov;250(5):720-8. doi: 10.1097/SLA.0b013e3181bdd840.
Clinical trial NCT00774332: A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
Official title: A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Acute Lymphoblastic Leukemia
Lead sponsor: Cooperative Study Group A for Hematology
Sponsor class: NETWORK
First posted: 2008-10-17
Enrollment: 37
Sex: ALL
Minimum age (years): 15
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL

Detailed description: The feasibility will be evaluated in terms of complete remission rate, duration of complete remission, disease-free survival, overall survival, and toxicities.

Eligibility criteria: Inclusion Criteria:

* Patients with relapsed/resistant acute lymphoblastic leukemia
* Patients must be between 15 and 65 years of age.
* Estimated life expectancy of more than 3 months
* ECOG performance status of 2 or lower, Karnofsky scale \> 60 (see appendix I)
* Adequate cardiac function (EF\>45%) on echocardiogram or MUGA scan
* Adequate kidney function (estimated Ccr \>50 ml/min)

Exclusion Criteria:

* Patients with CNS involvement of leukemic blasts will not be excluded.
* Patients with extramedullary relapse(s) only will be excluded.

Primary outcomes:
measure: Duration of complete remission, disease-free survival, overall survival, toxicities
timeFrame: 2009
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: Jung-Hee Lee, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05014932: Evaluation of Noise Induced by Ceramic-ceramic Friction Torques of Total Hip Prostheses With Customized Femoral Stem
Official title: Evaluation of Noise Induced by Ceramic-ceramic Friction Torques of Total Hip Prostheses With Customized Femoral Stem
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Arthroplasty Complications
Lead sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche
Sponsor class: OTHER
First posted: 2021-08-20
Enrollment: 531
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with at least two years of uncemented fourth generation ceramic/ceramic total hip replacement with customised femoral stem.

Brief summary: Evaluation of noise induced by ceramic-ceramic friction torques of total hip prostheses with customized femoral stem.

Retrospective and prospective multicentric study.

Detailed description: On a series of patients operated on for more than two years after a total hip arthroplasty that resulted in the implantation of a ceramic-on-ceramic prosthesis with a customized femoral stem:

Primary objective: To assess the frequency of occurrence of joint noise.

Secondary objectives:

* To describe the characteristics of the noise nuisance (date of onset, frequency, intensity, impact...)
* To evaluate the individual and surgical factors associated with the occurrence of noise pollution.

Eligibility criteria: Inclusion Criteria:

* Patient aged 18 years or older, who has been informed of the research
* Patient who has had a fourth generation ceramic/ceramic hip replacement implanted for at least two years as a first-line replacement
* Patient who has had a three-dimensional preoperative examination leading to the design and implantation of a custom femoral stem
* Patient regularly monitored since surgery and for whom all clinical and radiological data are available at the three-month and two-year follow-up visits

Exclusion Criteria:

* Patient operated for revision
* Patient under legal protection, guardianship or curators
* Patient who has indicated his opposition to the use of his medical data (by completing and returning the non-opposition form which will be sent to him)

Primary outcomes:
measure: Noise nuisance
timeFrame: 2 years
Secondary outcomes:
measure: Oxford Score
timeFrame: 2 years
measure: Hip disability and Osteoarthritis Outcome Score (HOOS) Score
timeFrame: 2 years
measure: Forgotten Joint Score
timeFrame: 2 years
measure: Prosthesis life span
timeFrame: 2 years
Other outcomes:
Locations:
city: Paris
country: France
facility: Clinique Maussins-Nollet
Study officials:
affiliation: Clinique Maussins-Nollet
name: Alexis NOGIER, MD PD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06344832: SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs
Official title: Somatostatin Receptor Antagonist PET/CT for Pre-operative N Stage Evaluation in Patients With Gastro-entero-pancreatic Neuroendocrine Tumors
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Gastro-entero-pancreatic Neuroendocrine Tumor
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2024-04-03
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with GEP-NEN undergoing surgical treatment at Peking Union Medical College Hospital.

Brief summary: The research aims to prospectively include patients with GEP-NENs, undergo preoperative imaging assessment (including PET/CT and contrast-enhanced CT), and accurately delineate lymph node regions. Through postoperative pathological reports, the diagnostic performance of lymph node metastasis (LNM) in GEP-NENs is evaluated. Factors influencing the diagnostic accuracy of SSTR-PET/CT and contrast-enhanced CT are also investigated.


Eligibility criteria: Inclusion Criteria:

1. Age \> 18 years old;
2. Patients diagnosed with GEP-NEN by surgical pathology;
3. Complete medical records including basic information and treatment process;
4. Patients who have undergone preoperative contrast-enhanced CT and 68Ga-SSTR-PET/CT, and have consented to the 68Ga-SSTR-PET/CT project in the Nuclear Medicine Department.

Exclusion Criteria:

1. Presence of concomitant malignancies;
2. Cases diagnosed pathologically as non-GEP-NEN.

Primary outcomes:
measure: lymph node metastasis status
timeFrame: 2024.04.01~2030.03.01
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01385332: A Comparative Study of Two Patterns of Controlled Ovarian Hyperstimulation in Mid Follicular Phase or Early Luteal Phase for Egg Donors
Official title: A Comparative Study of Two Patterns of Controlled Ovarian Hyperstimulation in Mid Follicular Phase or Early Luteal Phase for Egg Donors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stimulation in the Ovary
Keywords: Metaphase II
Ovarian stimulation
Egg donors
Lead sponsor: Parc de Salut Mar
Sponsor class: OTHER
First posted: 2011-06-30
Enrollment: 10
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the efficacy and safety of two new patterns of controlled ovarian hyperstimulation (defined as total number of picked up eggs). This study will be performed in egg donors but these new patterns will be implemented in fertility preservation patients.


Eligibility criteria: Inclusion Criteria:

* premenopausal women 18-30 years old, with FSH levels \< 10mIU
* irregular menstrual cycle
* BMI between 12-28
* signed inform consent

Exclusion Criteria:

* Polycystic ovarian syndrome, gonadotropins allergy

Primary outcomes:
measure: Number of eggs
timeFrame: Participants will be followed after 1-3 hrs of follicular aspiration.
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Servei de Ginecologia i Obstetricia, Hospital del Mar-Parc Salut Mar
Study officials:
References:
Clinical trial NCT05657132: Antibacterial Effect of New Herbal Paste Used as an Intracanal Medication
Official title: Antibacterial Effect of New Herbal Paste Used as an Intracanal Medication in Necrotic Primary Molars, a Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Infection Primary
Keywords: infected primary molars, metapaste, herbal paste
Lead sponsor: Nahda University
Sponsor class: OTHER
First posted: 2022-12-20
Enrollment: 24
Sex: ALL
Minimum age (years): 4
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized control trial
Primary purpose: TREATMENT

Brief summary: studying the antibacterial effect of Cosuts paste as an intracanal medication against Enterococcus faecalis that present in necrotic primary teeth

Detailed description: The children were randomly divided into two groups (I, II) Group I (N=12): using Costus-based paste as an intracanal medicament. Group II (N= 12): Calcium hydroxide iodoform paste (Metapex) as an intracanal medicament.

Procedure:

Access opening was started. then a swab was taken from the distal root canal with a dry paper point and transferred to a sterile test tube. The canals were filled with an intracanal medication according to the patient group. In group I, the canals was filled with a previously prepared Costus-based paste for one week, and In Group II, the canals were filled with Meta paste for one week. After 1 week, the paste was washed away from the canals then another swab was taken from the distal canal by a dry paper point as done before preoperatively.

The 2 swabs were transferred within 2 hours to the lab for bacterial culture and detection of enterococcus faecalis count.

Eligibility criteria: Inclusion Criteria:

* Patients with clinically and radiologically diagnosed infected primary teeth in their mandibular arch.
* Teeth should be deeply carious, with a history of spontaneous pain and carious exposures with necrotic pulp was also be selected
* radiographic evidence of adequate alveolar bone support, and absence of internal or external resorption.
* tooth must be restorable.

Exclusion Criteria:

* vital tooth
* Non restorable teeth

Primary outcomes:
measure: Bacterial count
timeFrame: 1 weak
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: NUB University
state: Bani Suif
Study officials:
affiliation: associate professor of Pediatric Dentistry
name: Ghada Salem, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06667232: Evaluating Modulation Effects of Burst Stimulation Patterns Using SEEG
Official title: Evaluating Modulation Effects of Burst Stimulation Patterns Using SEEG
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Epilepsy
Keywords: burst stimulation patterns
epilepsy
SEEG
Lead sponsor: Xuanwu Hospital, Beijing
Sponsor class: OTHER
First posted: 2024-10-31
Enrollment: 20
Sex: ALL
Minimum age (years): 14
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The study aims to evaluate modulation effects of burst stimulation patterns via SEEG.

Detailed description: Our research group plans to conduct a study on patients with drug-resistant epilepsy who have SEEG electrodes implanted. The study will evaluate and compare the modulation effect of single-pulse electrical stimulation, paired electrical stimulation, stepwise electrical stimulation, and burst electrical stimulation via direct electrical stimulation using SEEG. The goal is to explore the focal and network modulation effect of distinct stimulation paradigms during the resting state and post-seizure state.

Eligibility criteria: Inclusion Criteria:

* Drug-resistant focal epilepsy
* Justified SEEG exploration in the context of presurgical assessment of epilepsy
* Subjects will be a part of the epilepsy-monitoring unit for long-term SEEG recordings and analysis
* Written non-opposition to study participation

Exclusion Criteria:

* Pregnant women (Contraindication to SEEG exploration)
* Psychiatric disorders
* History of psychotic disorders
* History of cranial trauma serious (according to the classification), previous or evolutionary other neurological pathology
* Subjects that experience surgical complications during the implant procedure will be excluded from the study

Primary outcomes:
measure: Modulation Factor
timeFrame: During the trial(up to 3 hours for each subject)
measure: EEG power in spectral frequency bands
timeFrame: During the trial(up to 3 hours for each subject)
measure: Phase Locking Value
timeFrame: During the trial(up to 3 hours for each subject)
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Xuanwu Hospital,Capital Medical University
state: Beijing
Study officials:
affiliation: Xuanwu Hospital, Beijing
name: Liankun Ren, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06301932: The Effectiveness and Outcomes of Epidural Analgesia in Patients Undergoing Open Hepatectomy
Official title: The Effectiveness and Outcomes of Epidural Analgesia in Patients Undergoing Open Hepatectomy: A Propensity Score Matching Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epidural Analgesia
Patient Controlled Analgesia
Keywords: Liver resection
Propensity score matching
Lead sponsor: Chiang Mai University
Sponsor class: OTHER
First posted: 2024-03-08
Enrollment: 654
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients more than 18 years old, who underwent an open hepatectomy between January 2007 - December 2018 at Maharay Nakhon Chiangmai Hospital

Brief summary: This observational study is to compare the effectiveness and outcomes of epidural analgesia in patients undergoing open hepatectomy: A propensity score matching analysis.

The main question is: What is the superior method of pain control in open hepatectomy: epidural analgesia or intravenous PCA?

Detailed description: After approval of the study protocol from the institutional review board of Chiangmai University (Approval number: ANE-2562-06771), the investigators performed a retrospective review of all patients who underwent an elective open liver resection in the specialized hepato-biliary center from January 2007 through December 2018. This retrospective inquiry comprised 612 patients. The data was systematically retrieved from electronic medical records. Baseline characteristics including age, gender, body mass index (BMI), co-morbidity, American Society of Anesthesiologists (ASA) classification, diagnosis, hepatitis profile, Child-Pugh classification, cirrhosis, the largest tumor size, previous liver resection, and pre-operative laboratory investigations were collected. The following intra-operative data were collected: type of liver resection, hilar resection, vascular reconstruction, intra-operative opioid consumption and type of fluid administration, estimated blood loss, packed red cell and blood product transfusion, and operation time. Post-operative pain score and opioid consumption also be collected.

Eligibility criteria: Inclusion Criteria:

* All gender age above 18 years old
* Undergoing open liver resection surgery

Exclusion Criteria:

* No documentation of the numerical rating scale (NRS)
* Epidural failure

Primary outcomes:
measure: Post-operative opioid consumption
timeFrame: Within 72 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: